Abstract Library

#1812 Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study

Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Hörsch D, Hoffmanns P, Biran T, Houchard A,

Keywords: carcinoid syndrome, 5-HIAA, telotristat,

#1809 What Do We Know About Carcinoid Heart Disease? A Systematic Literature Review

Introduction: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Ovcinnikova O

Authors: Ovcinnikova O, Marshall M, Bagnati F, Hoffmanns P, Taveau ,

Keywords: carcinoid heart disease, systematic literature review, outcomes,

#1806 Epidemiology of Carcinoid Heart Disease (CHD) in Patients (pts) with Carcinoid Syndrome (CS): A Systematic Literature Review

Introduction: CHD develops in the context of CS due to the exposure of high levels of vasoactive substances, such as serotonin.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Ovcinnikova O

Authors: Ovcinnikova O, Marshall M, Bagnati F, Hoffmanns P, Taveau C,

Keywords: carcinoid syndrome, heart disease, epidemiology, prevalence, mortality,

#1737 The Role of MAPK-Signalling in Pancreatic Neuroendocrine Cancer

Introduction: Upon diagnosis, 65% of pNET patients suffer from metastatic or locally unresectable disease. The receptor tyrosine kinase inhibitor sunitinib and the mTOR inhibitor everolimus have set precedence for successful targeted therapies in pNET disease. However, response prediction and treatment alternatives still do not meet medical needs. Recent studies revealed mutations in RAS oncogenes in a fraction of tumours, emphasising a potential role of the MAPK pathway as therapeutic target.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Hoffmann J, Corbett L, Detjen K, Thedieck K, Sers C,

Keywords: pancreatic neuroendocrine tumors, MAPK pathway,

#1237 Risk Factors for Survival from Neuroendocrine Neoplasia with Unknown Primary Tumor Site

Introduction: Neuroendocrine neoplasia (NEN) with unknown primary site (NEN-CUP) may have a poor prognosis. We evaluated the clinical presentation, therapy, outcome, and risk factors for adverse outcomes in patients with NEN-CUP.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Begum N

Authors: Begum N, Wellner U, Thorns C, Hoffmann M, Bürk C,

Keywords: outcome, NEN-CUP, surgery, survival,